Elucidation of Hippo signaling and the functional implications of Hippo modulation in the heart are highly relevant and of great interest. Our previous work demonstrated that transgenic mice with cardiac-specific overexpression of Mst1 develop dilated cardiomyopathy with increased cardiomyocyte apoptosis. Interestingly, cardiomyocyte size in these mice was smaller than nontransgenic controls despite dilation of the heart and increased wall stress. These findings suggested that activation of Hippo promotes cardiomyocyte apoptosis, whereas compensatory hypertrophy is suppressed by Mst1. 5 We also observed that Lats2, a negative regulator
T he Drosophila Hippo pathway is an evolutionarily conserved signaling cascade and a key regulator of tissue growth and organ size.
1,2 Activation of the core complex (consisting of the kinases Hippo and Warts and the adapter proteins Salvador and Mats) leads to phosphorylation and inhibition of Yorkie, the transcription cofactor and terminal effector of the Hippo pathway. Conversely, Hippo pathway loss of function, or direct phosphorylation by homeodomain-interacting protein kinase 2, can elicit Yorkie activation. 3 Through association and activation of the transcription factor Scalloped, Yorkie regulates expression of cyclin E, diap1, and the microRNA (miRNA) bantam to promote proliferation and inhibit apoptosis. 1, 2 Hippo pathway components are highly conserved between flies and mammals, and mammalian homologs including Mst1/2 (Hippo), Lats1/2 (Warts), Yes-associated protein (YAP; Yorkie), and TEAD family transcription factors (Scalloped) exhibit similar, but not identical, regulation, and function outputs.
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of YAP, inhibits both hypertrophy and survival of cardiomyocytes during pressure overload stress. 6 Furthermore, disruption of endogenous cardiac YAP led to impaired compensatory hypertrophy, proliferation, and survival of cardiomyocytes during chronic myocardial infarction (MI) and ischemia/reperfusion (I/R). 7, 8 However, overexpression of constitutively active YAP promoted myocardial regeneration by stimulating cardiomyocyte proliferation. 9, 10 Previous reports have demonstrated the importance of cross talk between Hippo and IGF-Wnt/β-catenin pathways for cardiomyocyte proliferation during heart development. 11, 12 These results suggest that the Hippo pathway plays an essential role in cardiomyocyte biology and that YAP is an important mediator of the actions of the Hippo pathway in the heart. However, the mechanisms underlying how Hippo/YAP modulates cardiomyocyte growth and survival remain largely undefined. miRNAs regulate gene expression to affect cell growth, proliferation, and survival, and are important mediators of heart development, homeostasis, and disease. 13 miR-206 belongs to the miR-1/miR-206 family of miRNAs. miR-206 is expressed in several known tissues/cell types including the brain, 14, 15 cancer cell lines, 16 and brown adipocytes 17 and mediates multiple functions, including tissue growth and differentiation, 14, 15, 17, 18 suppression of angiogenesis, 19 as well as tumor suppression. 16 miR-206 and miR-1 have been shown to form clusters with miR-133b and miR-133a, respectively, and are critical factors for skeletal and cardiac muscle development and function. 20 In skeletal muscle, miR-206 positively regulates myogenesis, [21] [22] [23] hypertrophy 24 and regeneration, and delays the progression of amyotrophic lateral sclerosis 25 and Duchenne muscular dystrophy. 26 These findings suggest that miR-206 is an important modulator of striated muscle growth. Importantly, miR-206 is also present in cardiomyocytes, 27 but the cellular function of miR-206 in these cells is not well understood.
In this study, we explored the possibility that YAP regulates expression of miRNAs that modulate cardiomyocyte growth and survival. Through a microarray-based screening of miRNAs that showed altered expression in response to YAP, we found that the abundance of miR-206 was increased by YAP in cardiomyocytes. Despite some functional overlap between YAP and miR-206, a link between them has not been demonstrated. Therefore, the goals of this work were (1) to investigate the role of miR-206 in mediating the prohypertrophic and antiapoptotic actions of YAP in cardiomyocytes and (2) to identify the functional target of miR-206 in cardiomyocytes. Our results demonstrate that miR-206 mediates hypertrophy and cell survival stimulated by YAP through targeted degradation of the tumor suppressor, Forkhead box protein P1 (FoxP1).
Methods
An expanded Methods section is available in the online Data Supplement.
Adenoviral Vectors
Adenoviruses harboring genes of interest were made using the AdMax system (Microbix). Short hairpin RNA knockdown adenovirus for FoxP1 or miR-206 was made using the adenoviral shuttle vector pDC311 (Microbix), into which the U6 RNA polymerase III promoter and the polylinker region of pSilencer 1.0-U6 expression vector (Ambion) were subcloned. Sequence of sh-FoxP1: 5′-3′ GCCCACACTG CAGAGGAAAT TCAAGAGA TTTCCTCTGC AGTGTGGGC TTTTTT and sequence of anti-miR-206: 5′-3′ CGCGTCTCGA GCCACACACTTC CTTACATTCCA GCCCACA CACTTC CTTACATTCCAA.
Transgenic Mice
Tg-miR-206 and Tg-206-SPONGE mice were generated on an FVB background, using the α-myosin heavy chain promoter to achieve cardiac-specific expression of around 300 bp of the genomic region of miR-206 or 2 repeats of GFP-tagged miR-206 antisense, respectively. All protocols concerning animal use were approved by the Institutional Animal Care and Use Committee at Rutgers, New Jersey Medical School.
miRNA Microarray
Total RNA was isolated from YAP-and LacZ-transduced neonatal rat cardiomyocytes (NRCMs). Ten micrograms of RNA were sent to L.C. Sciences for a miRNA microarray. 28 Samples were enriched for small RNA, labeled with Cy3 and Cy5 fluorescent dyes and hybridized to a single Atactic μParaFlo microfluidics chip that held all 334 mature rodent miRNA probes identified to date, as well as perfectly matched and mismatched probes for quality control. Each miRNA probe is represented 9× on the microarray. Among the control probes, PUC2PM-20B and PUC2MM-20B are the perfect match and single-based match detection probes, respectively, of a 20-mer RNA-positive control sequence that is spiked into the RNA samples before labeling. One may assess assay stringency from the intensity ratio of PUC2PM-20B to PUC2MM-20B, which is normally larger than 30. After signal amplification, the background was subtracted and normalized using the LOWESS (locally weighted regression) method. For a transcript to be listed as detectable, it must meet the following criteria: signal intensity higher than 3× (background SD), spot coefficient of variation <0.5 (coefficient of variation=SD/signal intensity), and signals from at least 50% of the repeating probes above detection level.
Northern Blot
Total RNA, extracted using TRIzol reagent (Invitrogen), was separated on a 1% agarose gel, transferred to an uncharged nylon membrane, Hybond-NX (Amersham Biosciences), and UV cross-linked. The membrane was prehybridized/hybridized with MiracleHyb Hybridization solution according to the instruction manual (Stratagene). DNA oligonucleotides, antisense sequences of mature miRNAs, were obtained from Integrated DNA Technologies. The probes were 5′end labeled with ET adenosine 5′-triphosphate[γ- 32 P] (PerkinElmer) using a T4 Polynucleotide Kinase kit and used for hybridization (1×10 6 cpm/mL).
Statistics
All values are expressed as mean±SEM. Statistical analyses were performed using ANOVA or t test with a P<0.05 considered significant. To identify miRNAs involved in YAP-induced cardiac hypertrophy and survival, total RNA was extracted from NRCMs overexpressing wild-type YAP and enriched for small RNAs. We used microarrays containing rodent miRNAs to analyze the enriched extracts and selected miRNAs that showed the greatest increase in abundance, including miR-711, miR-483, and miR-206 (Online Table I ). Of note, we found no significant similarity in the nucleotide sequences between these miRNAs and the established Yorkie target bantam (Online Figure I) . Importantly, we found that overexpression of miR-206 significantly increased cardiomyocyte size (Online Figure  IIA) , whereas neither miR-711 nor miR-483 overexpression significantly affected cell size (Online Figure IIB) . In addition, a link between miR-206 expression and skeletal muscle hypertrophy has been demonstrated previously. 29 We therefore focused our efforts on investigating the possible role of miR-206 in mediating YAP-induced cardiac hypertrophy and survival for this study.
Nonstandard Abbreviations and Acronyms
Both Northern blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) confirmed our microarray result that the abundance of miR-206 was significantly increased (+1.44 fold by Northern blot and +2.13-fold by qRT-PCR) in cardiomyocytes overexpressing wild-type YAP, in which the activity of YAP was confirmed by TEAD luciferase activation (Figure 1A and 1B; Online Figure IIF) . Interestingly, YAP did not alter miR-206 levels in C2C12 mouse myoblasts, which have a higher abundance of miR-206 than NRCMs at baseline (Online Figure IIC) , suggesting that upregulation of miR-206 is cell type specific. Conversely, overexpression of Mst1, which induced inhibitory phosphorylation of YAP and reduced expression levels of the YAP target gene cardiac ankyrin repeat protein, decreased the abundance of miR-206 ( Figure 1C ; Online Figure IID ). In addition, coexpression of an Mst1-resistant form of YAP (Serine-127-Alanine) abolished the repressive effect of Mst1 on miR-206 abundance (Online Figure IIE) , indicating that the mammalian Hippo pathway suppresses miR-206 expression in cardiomyocytes.
Given the reported similarity between miR-1 and miR-206, 30 we sequenced the qPCR products detected by the miR-206 and miR-1 qPCR primers to ensure their intended mature miRNA sequences were measured (Online Figure IIIA) . The specificity of the Taqman MicroRNA Assay was further verified in that qRT-PCR did not detect an increase in miR-206 in cardiomyocytes transduced with miR-1 adenovirus (Online Figure IIIB) .
To investigate the mechanism by which YAP increases the abundance of miR-206, we focused on the role of enhancer box (E-box) elements in modulating miR-206 transcriptional activation. We constructed luciferase reporters containing either the wild-type miR-206 enhancer with 9 E-box sites or a mutant enhancer with mutations in the 3 most conserved E-box sites (E-box-3 m) ( Figure 1D ). YAP significantly activated the wild-type E-box, but not E-box-3 m enhancerluciferase reporter, compared with control luciferase reporter ( Figure 1E ). However, Mst1 significantly decreased the E-box luciferase activity ( Figure 1F ). We also performed chromatin immunoprecipitation to test whether YAP associates with the miR-206 E-box. ChIP showed that YAP binds to the E-box located in the miR-206 promoter ( Figure 1G ). This suggests that the Hippo pathway inhibits miR-206 transcription through the E-box elements. Moreover, YAP did not stimulate the miR-1 enhancer-luciferase reporter, indicating that YAP selectively upregulates miR-206 and not miR-1 expression in cardiomyocytes (Online Figure IVA) .
miR-206 Induces Cardiac Hypertrophy and Protects Myocytes From Death
Transduction of NRCMs with adenovirus harboring miR-206 (Ad-miR-206) induced upregulation of mature miR-206, as evaluated by Northern blot (Figure 2A ). Adenoviral-mediated expression of either miR-206 or YAP for 48 hours induced cardiomyocyte hypertrophy, as evidenced by an increase in cell size and the total protein content normalized to DNA content ( Figure 2B and 2C) . Similarly, miR-206 and YAP both significantly increased mRNA expression of atrial natriuretic factor (ANF), a hypertrophic marker gene, 31 as well as activation of the ANF-luciferase reporter gene in cardiomyocytes. ANF-luciferase activation was comparable with that elicited by phenylephrine, an α-1 adrenergic agonist known to stimulate cardiac hypertrophy 32 and used here as a positive control to promote cardiac hypertrophy ( Figure 2D and 2E ). In contrast, miR-1 expression did not increase total protein normalized to DNA content in cardiomyocytes (Online Figure IVB) . These results suggest that upregulation of miR-206 is sufficient to induce cardiomyocyte hypertrophy in vitro, whereas upregulation of miR-1 is not.
To examine the effect of miR-206 on cell death, cardiomyocytes were treated with chelerythrine, a known inducer of apoptosis. Figure IVE) .
To test whether miR-206 is sufficient to induce cardiac hypertrophy in vivo, we generated 4 lines of transgenic (Tg) mice with cardiac-specific expression of the genomic region (≈300 bp) of miR-206, driven by the α-myosin heavy chain promoter (Tg-miR-206). Mature miR-206 was upregulated in Tg-miR-206 mouse myocardium compared with nontransgenic (NTg) controls, as shown by Northern blot analysis ( Figure 3A ; Online Figure VA , left). Although we observed a modest increase in miR-1 levels by Northern blot, this was most probably because of detection of ectopic miR-206 by the miR-1 Northern probe, which, because of the nature of its design, has less selectivity compared with the qRT-PCR probes. In fact, we did not observe any increase in miR-1 expression levels using qRT-PCR analysis of Tg-miR-206 hearts compared with NTg (Online Figure VA, right) . In . Nine wild-type or mutated E-box sites were included in the promoters of the luciferase reporter used in E and F (bottom right). E and F, Cardiomyocytes were transduced with Ad-YAP, Ad-Mst1, or Ad-LacZ and then transfected with luciferase reporter constructs harboring either a control, wild-type E-box or mutated E-box sequence in the promoter, n=4 (E) and 3 (F). G, YAPoverexpressing cardiomyocytes were harvested for ChIP assays. ChIP assays were conducted with antibodies against YAP or a control immunoglobulin G (IgG) and specific E-box primers. PCR using input DNA as a template served as an internal control, n=3. CARP indicates cardiac ankyrin repeat protein.
by guest on April 15, 2017 http://circres.ahajournals.org/
Downloaded from

Yang et al miR-206 Mediates Hypertrophy and Survival 895
Tg-miR-206 mice ( Figure 3H and 3I). Taken together, these results suggest that miR-206 expression induces cardiac hypertrophy in vivo. Although we generated multiple lines of transgenic mice, none of the lines exhibited low levels of miR-206 overexpression. Thus, it is possible that the cardiac phenotype observed in Tg-miR-206 may not reflect physiological function of miR-206.
To address this issue in part, we also used a complimentary loss-of-function approach to test the involvement of miR-206 in cardiac hypertrophy. Wild-type C57B/6J mice were administered LNA inhibitor designed to selectively inhibit miR-206, or control scrambled LNA, by tail vein injection. Specificity of the LNA inhibitor was confirmed by qRT-PCR analysis of miRNA expression 7 days after treatment (Online Figure VG) . After 7 days, mice from both treatment groups were subjected to sham operation or transverse aortic constriction (TAC) to elicit hemodynamic overload. After 7 days of TAC, echocardiography was performed and mice were euthanized. Importantly, we found upregulation of myocardial miR-206 expression levels after 7 days TAC, consistent with its observed prohypertrophic effect (Online Figure VH) . A significant increase in LV weight /tibia length 
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in LNA control-treated mice after TAC was observed; however, no increase was observed in LNA-anti-206-treated mice ( Figure 3J ). We also noted significant differences in chamber wall thickness between the control and anti-206 TAC groups (Online Table II ). In addition, cardiomyocyte cross-sectional area and ANF expression were significantly increased in the LNA control-treated TAC group, and these responses were attenuated in the LNA-anti-206-treated mice (Figure 3K and 3L; Online Figure VI ). These data demonstrate that inhibition of miR-206 impairs pressure overload-induced hypertrophy and indicates that miR-206 is an important endogenous promoter of heart growth in response to stress.
miR-206 Is an Important Mediator of YAP-Induced Cardiac Hypertrophy and Inhibition of Cardiac Cell Death
To . J-L, Wild-type C57B6 male mice were treated with LNA scrambled control or LNA-anti-206 by tail vein injection 7 days before intervention. Groups were subjected to 1-week transverse aortic constriction (TAC) or sham operation. J, LV weight/tibia length (LVW/TL) was determined. K, Heart sections were stained with WGA and cardiomyocyte CSA was determined. L, mRNA was isolated from ventricles and subjected to qRT-PCR to detect ANF levels, n=4 to 6. A, Cardiomyocytes were harvested for Northern blot, using an miR-206 probe or an miR-1 probe. RNA loading was evaluated with ethidium bromide staining. The level of miR-206 and miR-1 was normalized by that of 5S rRNA, n=5. B, Cardiomyocytes were stained with anti-α-actinin antibody (red) and 4′,6-diamidino-2-phenylindole (DAPI; blue), and relative cell surface area (cell size) was evaluated. Scale bar, 30 μm, n=3. C, Cardiomyocytes were harvested for the measurement of total protein content normalized by DNA content, n=3. D, Cardiomyocytes were stained with anti-atrial natriuretic factor (ANF) antibody and DAPI. ANF-positive cells were quantified, n=3. E, Cardiomyocytes were transfected with ANF-luciferase reporter gene and either Pdc-U6 or Pdc-anti-206 plasmids before transduction with Ad-LacZ or Ad-YAP. After 48 hours, myocytes were harvested for ANF-luciferase activity measurements, n=4. F, Cardiomyocytes were harvested for Cell Titer Blue assays, n=3. G, Cardiomyocytes were treated with or without chelerythrine (5 μmol/L) for 1 hour and harvested for immunoblot analyses with anti-cleaved caspase-3 (Cleaved-Casp3) antibody and the results were quantified by densitometry, n=4. 
Endogenous miR-206 Is Protective During I/R Injury
To examine the physiological function of miR-206 during stress, we first examined miR-206 expression in response to oxidative stress. H 2 O 2 treatment reduced RNA and protein levels of miR-206 and YAP, respectively, in cardiomyocytes (Figure 5A and 5B; Online Figure VIIA) . Similarly, miR-206 and YAP were downregulated in mouse hearts subjected to ischemia followed by reperfusion compared with sham-operated controls (Figure 5C and 5D; Online Figure VIIB and VIIC). In contrast, miR-1 was upregulated in response to ischemia followed by reperfusion (Online Figure VIID) . To evaluate the role of endogenous miR-206 in mediating cardiomyocyte survival in vivo, we used Tg-206-SPONGE mice, which have reduced miR-206, but not miR-1, expression compared with NTg controls ( Figure 5E ; Online Figure VIIE and VIIF). We found that I/R-induced cardiac injury was exacerbated in Tg-206-SPONGE compared with NTg mice, as indicated by a greater size of MI normalized by the area at risk (Figure 5F and 5G). In contrast, the size of MI normalized by the area at risk after I/R was significantly reduced in Tg-miR-206 compared with NTg hearts (Figure 5H and 5I). To test whether increased miR-206 expression can mitigate the chronic effects of I/R injury, including decreased cardiac function, we subjected NTg and Tg-miR-206 mice to I/R and followed them with serial echocardiography. Although there was no difference in basal heart function between Tg-miR-206 and NTg mice, we found that Tg-miR-206 mice had significantly better cardiac function, as determined by percent fractional shortening, post I/R compared with NTg controls (Online Figure VIIG) . These results suggest that downregulation of endogenous miR-206 promotes myocardial I/R injury, whereas restoration of miR-206 levels with exogenous miR-206 protects against I/R injury and counteracts the progression to heart failure. Figure VIIIA) further strengthening our rationale to investigate FoxP1. To demonstrate that FoxP1 is a target of miR-206, we first conducted luciferase assays using the FoxP1 3′UTR. The 3′UTR of the luciferase gene was replaced with either the WT FoxP1 3′UTR or a mutated FoxP1 3′UTR, in which the miR-206 binding sites were altered. Transduction of NRCMs with Ad-miR-206, but not Ad-scrambled, significantly inhibited the luciferase reporter containing the WT FoxP1 3′UTR; however, the luciferase reporter containing the mutated FoxP1 3′UTR was not affected ( Figure 6A) . Conversely, an miRID-IAN miR-206 inhibitor, but not control miRIDIAN inhibitor, significantly stimulated the luciferase reporter containing the WT FoxP1 3′UTR but did not affect the control reporter containing the mutated FoxP1 3′UTR (Online Figure VIC) . Adenoviral-mediated expression of either YAP or miR-206 in cardiomyocytes inhibited FoxP1 expression, as determined by Western blotting (Figure 6B and 6C) . Figure 6D ), whereas it was upregulated in Tg-206-SPONGE mice, in which endogenous miR-206 is suppressed ( Figure 6E ). The upregulation of FoxP1 observed in Tg-206-SPONGE mice was normalized when Tg-206-SPONGE mice were crossed with Tg-miR-206 mice ( Figure 6E ). Taken together, these results suggest that FoxP1 is a specific target of miR-206 in the heart and the cardiomyocytes therein. On the basis of our hypothesis, we predicted that FoxP1 inhibits cardiac hypertrophy. To test this, cultured cardiomyocytes were transduced with an adenovirus harboring shRNA targeting FoxP1 (Ad-sh-FoxP1). We confirmed that Ad-sh-FoxP1 efficiently downregulated both endogenous and overexpressed FoxP1 in cardiomyocytes ( Figure 7A ; Online Figure VIIID) . Downregulation of FoxP1 significantly increased cell size at baseline ( Figure 7B ) and increased cell viability after H 2 O 2 treatment (Online Figure VIIIG) , indicating that endogenous FoxP1 negatively regulates cardiomyocyte hypertrophy and survival.
To elucidate the contribution of FoxP1 downregulation to the overall effect of miR-206 in cardiomyocytes, we generated an adenoviral vector harboring FoxP1 (Ad-FoxP1). We confirmed that FoxP1 is overexpressed in Ad-FoxP1-transduced Both miR-206-and YAP-induced cardiomyocyte hypertrophy, as evaluated by cell size, were significantly attenuated when FoxP1 levels were normalized by adenoviral-mediated FoxP1 expression ( Figure 7C and 7D, bottom) . These results indicate that YAP/miR-206 induce cardiomyocyte hypertrophy through downregulation of FoxP1. We then tested the involvement of FoxP1 in mediating the protective effect of YAP and miR-206. We found that when FoxP1 levels were normalized, the ability of miR-206 to inhibit chelerythrine-induced cardiomyocyte death was abrogated (Figure 7E and 7F; Online Figure VIIIH) . Interestingly, protection conferred by YAP was partially but not completely inhibited by FoxP1 ( Figure 7G ), suggesting that miR-206 promotes cell survival through downregulation of FoxP1, whereas YAP probably promotes survival through additional mechanisms. Recent work has demonstrated that YAP upregulates miR-29, which in turn inhibits PTEN and activates the mTOR pathway. 34 In cardiomyocytes, we found that YAP upregulated miR-29 1.9-fold (Online Table I ) indicating that regulation of miR-29 by YAP may occur in multiple cell and tissue types. Although 1 study reported that miR-29c induces modest enlargement of NRCMs, 35 our results show that overexpression of miR-29 did not induce hypertrophy in NRCMs (Online Figure IIB) . Previous work has shown that miR-29 is enriched in cardiac fibroblasts and inhibits cardiac fibrosis. 36 In addition, miR-29 was found to negatively regulate cardiomyocyte proliferation during postnatal cardiac development demonstrating that miR-29 does play a role in cardiovascular biology. 37 Thus, miR-29 is likely to mediate additional nongrowth-related functions of YAP in cardiomyocytes.
The enhancer region of miR-206 does not contain typical binding sites for the reported mammalian transcriptional partners of YAP, including TEAD, RUNX, ErbB4, p73, Tbx5, or Smad. 4 Instead, we found that E-box elements are present in the miR-206 enhancer region and that 3 conserved E-box elements on the miR-206 enhancer are critical for basal, as well as YAP-induced, miR-206 expression in cardiomyocytes ( Figure 1E ). It has been shown that myogenic factors induce expression of muscle-specific miRNAs (including miR-1, miR-206, and miR-133) by binding to E-box regions in the promoter/enhancer. 22, 38 However, the identity of the E-box-binding transcription factor responsible for YAP-induced upregulation of miR-206 and its functional relationship to YAP remain to be demonstrated and warrant future investigation.
We have demonstrated that both YAP and miR-206 stimulate hypertrophy and survival of cardiomyocytes in vitro. In vivo, exogenous expression of either YAP or miR-206 protects cardiomyocytes against I/R-induced death and reduces heart injury. 8 Furthermore, cardiac-specific heterozygous deletion of Yap1 promotes cardiac dysfunction but inhibits cardiac hypertrophy during chronic MI, suggesting that endogenous YAP plays an important role in promoting both survival and hypertrophy during cardiac remodeling in the adult mouse heart. 7 In addition, we found that overexpression of miR-206 in the mouse heart induces hypertrophy without cardiac dysfunction, and that selective inhibition of miR-206 prevents 1-week TAC-induced hypertrophy without altering cardiac function. Taken altogether, we speculate that the YAP-miR-206 pathway may mediate physiological hypertrophy, and serves a compensatory function to help protect the heart against increased demand and stress. Interestingly, although phosphatidylinositol 3-kinase has been shown to promote physiological hypertrophy, 39 we previously reported that YAP-induced cardiac hypertrophy was not affected by phosphatidylinositol 3-kinase inhibition, 7 suggesting that the YAP-miR-206 pathway mediates physiological hypertrophy through PI3K-independent mechanisms. We have shown previously that YAP is activated in the peri-infarct area in the post-MI heart. 7 Although YAP is activated by mechanical stress and agonists of G-proteincoupled receptors in other cell types, 40, 41 how YAP is activated in response to hypertrophic stimuli remains to be elucidated in cardiomyocytes.
Expression of miR-206 is relatively low at baseline and is further downregulated in response to oxidative stress in cardiomyocytes and I/R in the heart. This is consistent with our previous findings that both oxidative stress and I/R activate Mst1 and Lats2, which would in turn inhibit YAP. 5, 42, 43 Because further downregulation of miR-206 exacerbated I/R injury ( Figure 5F and 5G), whereas exogenous miR-206 expression reduced injury, endogenous miR-206 seems to have an essential role in promoting survival of cardiomyocytes during I/R. We also found that miR-206 expression was sufficient to counteract the decreased cardiac function observed in response to chronic I/R, further evidence of the cardioprotective effect of miR-206 in vivo.
We speculate that the effect of YAP on growth and survival of cardiomyocytes functions through multiple mechanisms in a context-dependent manner. YAP regulates proliferation of cardiomyocytes through YAP-TEAD interaction. 44 We have shown recently that YAP acts as a nuclear cofactor of FoxO1 to protect the heart during myocardial I/R. 8 Furthermore, YAP has been shown to regulate global biogenesis and processing of miRNA through an interaction with p72 (DDX17) 45 and let-7-dependent downregulation of Dicer, 46 respectively. Further investigation is required to elucidate the relative importance of these mechanisms in the regulation of growth and death of cardiomyocytes by YAP.
Our results indicate that FoxP1 is a physiological mediator of miR-206 function in cardiomyocytes. First, we found that its 3′UTR is specifically targeted by miR-206. In NRCMs, Figure 6E ). Although FoxP1 has been identified as a target of miR-1 in certain cell types, 47 we clearly demonstrate that FoxP1 is specifically targeted by miR-206, and not by miR-1, in cardiomyocytes (Online Figure VIIIC) .
Second, we demonstrate that FoxP1 is an endogenous negative regulator of cardiac hypertrophy and survival. Indeed, downregulation of FoxP1 was sufficient to induce hypertrophy and to promote cell survival in cultured cardiomyocytes ( Figure 7B ; Online Figure VIIIG) . Furthermore, both the stimulation of hypertrophy and the suppression of apoptosis by miR-206 were attenuated when FoxP1 downregulation was reversed by adenoviral supplementation of FoxP1 in cardiomyocytes ( Figure 7C , 7E, and 7F; Online Figure VIIIH) . Taken together, our results suggest that downregulation of FoxP1 plays an important role in mediating the effects of miR-206 in cardiomyocytes.
FoxP1 systemic knockout mice die at E14.5 because of heart failure. 48 These mice exhibit defects in valve formation caused by impaired apoptosis in the endocardial cushion mesenchyme, and have a thinner ventricular compact zone because of increased proliferation of the ventricular trabecular zone. 48 Cardiac-specific FoxP1 knockout mice die within 24 hours of birth and have a thickened myocardium resulting from increased myocyte proliferation in a cell-autonomous fashion. 49 These data suggest that FoxP1 promotes apoptosis and inhibits cardiomyocyte proliferation during cardiac development. FoxP1 also negatively regulates cardiac hypertrophy by interacting with and inhibiting Nfat3 transcriptional activity. 50 It will be interesting to clarify the involvement of miR-206 in these cardiac events through FoxP1 targeting. In addition, FoxP1 is abundant in the nuclei of cardiomyocytes in failing human hearts.
51 Because Mst1, a negative regulator of YAP, is activated in the failing heart, 52 upregulation of FoxP1 may be mediated through downregulation of miR-206. The roles of miR-206 and FoxP1 in regulating myocardial cell death in the failing heart remain to be elucidated.
Some limitations in this study should be noted. First, the absolute level of miR-206 in the heart and the cardiomyocytes therein is low compared with skeletal muscle and the skeletal myocytes therein. Although we conducted multiple loss-of-function experiments, using anti-miRNA, SPONGE, LNA anti-miR, and miRIDIAN inhibitor, the functional importance of endogenous miR-206 requires further scrutiny, for example, by using cardiac-specific miR-206 knockout mice. Second, increasing lines of evidence suggest that organs can take up miRNA from the circulation. 53 Although the level of miR-206 in the circulation is low, it can be released from skeletal muscle after heavy workload, such as marathon running. 54 Thus, we cannot formally exclude the possibility that exogenous, rather than endogenous, miR-206, such as that which originates from skeletal muscle, affects the function of the heart. Again, studies using skeletal muscle-specific miR-206 knockout mice would be helpful to address this issue.
In summary, we show here that miR-206 is upregulated by YAP and mediates YAP-induced hypertrophy and cardiomyocyte survival. The expression of miR-206 is regulated in response to I/R and oxidative stress. miR-206 promotes cardiomyocyte survival and cardiac hypertrophy in vivo, which in turn contributes to the regulation of myocardial injury and organ size. We also identify FoxP1 as a novel and critical downstream target of miR-206 that mediates its effects on cardiomyocyte survival and hypertrophy. To our knowledge, this is the first report demonstrating a functional miRNA target of YAP in cardiomyocytes that affects heart growth, death, and function. What Is Known?
• Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ size by modulating cell growth, proliferation, and apoptosis.
• YAP is a transcription cofactor, which can regulate multiple transcription factors, including TEAD, RUNX, TBX5, and FOXO.
• YAP promotes cardiomyocyte survival and proliferation in the postnatal heart, and cardiac regeneration and remodeling after myocardial infarction.
What New Information Does This Article Contribute?
• YAP upregulates miR-206, which in turn plays an important role in mediating the effect of YAP on cardiomyocyte survival and hypertrophy.
• miR-206 promotes cardiomyocyte survival during ischemia/reperfusion in the heart. • miR-206 mediates cardiomyocyte hypertrophy and survival through inhibitory targeting of Forkhead box protein P1.
Increasing lines of evidence suggest that the Hippo pathway plays an important role in regulating the growth and death of cardiomyocytes by negatively regulating YAP, a transcription cofactor. The nuclear localization of YAP is negatively regulated by 2 upstream kinases, MST1 and LATS2, which constitute the core of the Hippo pathway. YAP that is localized in the nucleus positively regulates cardiomyocyte proliferation, hypertrophy, and survival. YAP is known to exert its function through TEAD and other transcription factors. However, the role of YAP in regulating miRNAs in the heart is unknown. We show that YAP transcriptionally upregulates miR-206, which in turn mediates the effect of YAP on cardiomyocyte hypertrophy and survival. Endogenous miR-206 also plays an essential role in mediating pressure overload-induced cardiac hypertrophy and cardiomyocyte survival during ischemia/reperfusion. One of the important targets of miR-206 is Forkhead box protein P1. Inhibition of Forkhead box protein P1 mediates the effect of miR-206 on cardiomyocyte hypertrophy and survival. Taken together, our results suggest that miR-206 is an important downstream effector of YAP that mediates both hypertrophy and cardiomyocyte survival at baseline and in response to stress. The YAP-miR-206 pathway seems to be a promising target for treatment of heart disease through modulation of myocardial growth and death mechanisms. Evaluation of apoptosis in cardiomyocytes DNA fragmentation was detected in cultured cells using TUNEL as described previously 1 . Nuclear density was determined by counting DAPIstained nuclei in 20 different fields for each sample.
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Materials
Ischemia/reperfusion
The ischemia/reperfusion (I/R) procedure has been described previously 4 .
In brief, ischemia was achieved by ligating the anterior descending branch of the LAD using an 8-0 nylon suture, with a silicon tubing (1 mm OD) placed on top of the LAD, 2 mm below the border between the left atrium and LV. Regional ischemia was confirmed by ECG change (ST elevation). After occlusion for 45 minutes, the silicon tubing was removed to achieve reperfusion.
Assessment of area at risk and infarct size After 45 minutes of ischemia and 24 hours of reperfusion, mice were reanesthetized and intubated, and the chest was opened. After arresting the heart at the diastolic phase by KCl injection, the ascending aorta was cannulated and perfused with saline to wash out blood. The LAD was occluded with the same suture, which had been left at the site of the ligation. To demarcate the ischemic area at risk (AAR), Alcian blue dye (1%) was perfused into the aorta and coronary arteries. Hearts were excised, and LVs were sliced into six 1-mm-thick cross-sections. The heart sections were then incubated with a 1% triphenyltetrazolium chloride (TTC) solution at 37°C for 12 minutes. The infarct area (pale), the AAR (not blue) and the total LV area from both sides of each section were measured using Echocardiography Mice were anesthetized using 12 μl/g body weight of 2.5% tribromoethanol (Avertin, Sigma), and echocardiography was performed as described previously Histological analysis Heart specimens were fixed with formalin, embedded in paraffin, and sectioned at 6-μm thickness. Cardiomyocyte cross-sectional area was measured from images captured from wheat germ agglutinin-stained sections as described previously 5 .
Immunohistochemistry Heart sections were stained with anti-Ki67 rabbit polyclonal antibody 
